{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["101"],"submitter":["Ghadimi N"],"pubmed_abstract":["<h4>Background</h4>With the rising burden of cardiovascular disease (CVD) and the need for cost-effective interventions, evaluating the economic implications of Evolocumab becomes crucial.<h4>Objectives</h4>This study aimed to systematically review and evaluate the cost-effectiveness of Evolocumab in adults at risk of CVD.<h4>Methods</h4>We performed an extensive search in Cochrane Library, EMBASE, PubMed, ProQuest, and Web of Science. The reference lists of chosen literature reviews were also examined to find suitable cost-effectiveness analyses (CEAs) of Evolocumab in patients with CVD published until March 2023. The Consolidated Health Economic Evaluation Reporting Standards statement (CHEERS) was used to assess the reporting quality. Cost-related findings were adjusted to reflect 2023 "],"journal":["Current therapeutic research, clinical and experimental"],"pagination":["100758"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11513655"],"repository":["biostudies-literature"],"pubmed_title":["Cost-effectiveness of Evolocumab in Cardiovascular Disease: A Systematic Review."],"pmcid":["PMC11513655"],"pubmed_authors":["Goharimehr M","Khodamorzideh D","Kaveh S","Shabaninejad H","Daroudi R","Ghadimi N"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness of Evolocumab in Cardiovascular Disease: A Systematic Review.","description":"<h4>Background</h4>With the rising burden of cardiovascular disease (CVD) and the need for cost-effective interventions, evaluating the economic implications of Evolocumab becomes crucial.<h4>Objectives</h4>This study aimed to systematically review and evaluate the cost-effectiveness of Evolocumab in adults at risk of CVD.<h4>Methods</h4>We performed an extensive search in Cochrane Library, EMBASE, PubMed, ProQuest, and Web of Science. The reference lists of chosen literature reviews were also examined to find suitable cost-effectiveness analyses (CEAs) of Evolocumab in patients with CVD published until March 2023. The Consolidated Health Economic Evaluation Reporting Standards statement (CHEERS) was used to assess the reporting quality. Cost-related findings were adjusted to reflect 2023 ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-06-02T04:56:51.337Z","creation":"2025-04-04T00:29:41.354Z"},"accession":"S-EPMC11513655","cross_references":{"pubmed":["39469092"],"doi":["10.1016/j.curtheres.2024.100758"]}}